Nippon India Pharma Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 12-04-2024

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund-Growth Plan-Growth 0.47 4.88 51.59 17.19 22.73 20.79
S&P BSE Health Care - TRI 2.14 8.22 55.15 16.81 20.31 15.32
S&P BSE SENSEX - TRI 0.78 2.46 24.56 17.13 15.21 13.68

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 51.59 17.19 22.73 1.83 7,125.28
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 54.68 19.40 23.26 2.01 2,626.34
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 50.10 15.14 20.81 2.33 947.26

Fund Holdings as on 31-March-2024

  • Sun Pharmaceutical Industries Limited

  • Lupin Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • Dr. Reddy's Laboratories Limited

  • Gland Pharma Limited

  • Divi's Laboratories Limited

  • Zydus Lifesciences Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Abbott India Limited

  • Ajanta Pharma Limited

  • MedPlus Health Services Limited

  • Mankind Pharma Limited

  • Vijaya Diagnostic Centre Limited

  • Aurobindo Pharma Limited

  • Narayana Hrudayalaya Limited

  • Sanofi India Limited

  • Alkem Laboratories Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Torrent Pharmaceuticals Limited

  • Pfizer Limited

  • Fortis Healthcare Limited

  • Triparty Repo

  • Thyrocare Technologies Limited

  • Nippon India Liquid Fund-Direct Growth Plan

  • Syngene International Limited

  • Orchid Pharma Limited

  • Indoco Remedies Limited

  • Concord Biotech Limited

  • Metropolis Healthcare Limited

  • AstraZeneca Pharma India Limited

  • Jubilant Pharmova Limited

  • Healthcare Global Enterprises Limited

  • Cash Margin - CCIL

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Business Support

View More

Fund Manager

  • Cash

  • Equity

  • MFU

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹7,125.28 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-4.99(-1.16%)yesterday to ₹426.3983.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097